TerminatedPhase 1

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Stopped: Closed because of feasibility and safety issues, didn't reach our end point

United States3 participantsStarted 2020-10-07

Plain-language summary

To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is suppressed from attacking these special tumor fighting cells.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Not candidates for known curative intent therapy.
✓. Progressed following at least one prior systemic therapy.
✓. Have advanced melanoma unresectable stage III or stage IV
✓. Have advanced head and neck recurrent or metastatic disease

What they're measuring

Dose Limiting Toxicity

Timeframe: 2 months

Trial details

NCT IDNCT03991741

SponsorGregory Daniels

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-01-26

Results submitted2025-01-14

View on ClinicalTrials.gov More Metastatic Melanoma trials